High-quality, highly specific antibodies are indispensable tools for dissecting disease mechanisms and advancing therapeutic development. Among the vast array of cell-surface and secreted proteins, VEGF, CD171, and CD79B have emerged as critical targets in angiogenesis, neuro-oncology, and B-cell immunology, respectively. Monoclonal antibodies and recombinant proteins against these markers enable precise detection, functional interrogation, and therapeutic targeting—driving breakthroughs from fundamental biology to translational medicine.

VEGF Antibodies: The Gold Standard for Studying Angiogenesis and Vascular Biology

Vascular Endothelial Growth Factor(VEGF) antibodies represent a cornerstone of modern targeted therapy, with profound implications across oncology and ophthalmology. These biologics function by neutralizing VEGF-A, the primary ligand responsible for pathological angiogenesis and vascular hyperpermeability, thereby disrupting a critical signaling axis that fuels tumor growth and retinal disease. The clinical success of anti-VEGF antibodies stems from a deep understanding of the VEGF/VEGFR2 signaling pathway, where VEGF binding to its principal receptor, VEGFR2, on endothelial cells triggers intracellular cascades (including MAPK/ERK and PI3K/AKT) that drive proliferation, migration, survival, and increased vascular permeability. By intercepting this signal extracellularly, these antibodies induce a cascade of beneficial effects: in tumors, they cause regression of immature, dysfunctional vessels and transiently "normalize" the remaining vasculature, improving perfusion and oxygenation; in the eye, they seal leaky retinal capillaries and inhibit the growth of destructive new blood vessels.The two most prominent anti-VEGF antibodies are bevacizumab and ranibizumab, which, despite targeting the same ligand, were engineered for distinct therapeutic niches. Despite its systemic origins, bevacizumab is also used extensively off-label in ophthalmology due to its lower cost.

CD171 Antibodies: Essential Probes for Neural Development and Cancer Metastasis Research

CD171, also known as L1 cell adhesion molecule (L1CAM), is a transmembrane glycoprotein expressed on neurons, lymphocytes, and certain tumours. It mediates cell-cell adhesion and signalling, playing critical roles in neural development, axon guidance, and immune cell interactions.

CD171 antibodies are increasingly sought after for:

· Neurodevelopmental studies: CD171 is a key regulator of neuronal migration, axonal growth, and synaptic plasticity. CD171 monoclonal antibodies allow researchers to track L1CAM expression during neural development and investigate its role in axon guidance and neuronal connectivity.

· Cancer metastasis research: Overexpression of CD171 is strongly linked to cancer metastasis and poor prognosis in multiple tumour types, including colorectal, ovarian, and pancreatic cancer. CD171 antibodies are essential for identifying L1CAM-positive circulating tumour cells and studying the molecular mechanisms of metastatic spread.

· Immunology and lymphocyte function: CD171 is also expressed on activated lymphocytes and participates in immune cell adhesion and migration. Anti-CD171 antibodies facilitate the study of L1CAM’s role in T-cell trafficking and immune synapse formation.

CD79B Antibodies and Proteins: Key Tools for B\u001eCell Receptor Signalling and Lymphoma Research

CD79B, also known as Igβ or B29, is a critical transmembrane signaling component of the B-cell receptor (BCR) complex, forming an indispensable heterodimer with its partner CD79A (Igα or mb-1). This complex is fundamental to B-cell biology, serving not only as the primary conduit for antigen-induced activation signals but also as a master regulator of BCR assembly, surface expression, and cellular fitness. The therapeutic and diagnostic significance of CD79B has grown substantially due to its highly restricted expression on B cells—from early pre-B cell stages through mature B cells—and its frequent, though heterogeneous, presence on malignant B-cell populations in lymphomas and leukemias. This makes it an attractive target for precision therapies like antibody-drug conjugates (ADCs) and a valuable marker for immunophenotyping.

The molecular architecture of CD79B underpins its dual functionality. Its extracellular domain, which is targeted by therapeutic antibodies, facilitates dimerization with CD79A. The intracellular tail contains an immunoreceptor tyrosine-based activation motif (ITAM), which, upon phosphorylation by Src-family kinases following antigen binding to the BCR, recruits and activates Syk kinase, thereby initiating a cascade of downstream signaling events essential for B-cell activation, proliferation, and differentiation.

CD79B antibodies and recombinant proteins are indispensable for:

· B-cell signalling research: CD79B is essential for BCR assembly, surface expression, and signal transduction. CD79B antibodies enable detailed dissection of BCR-mediated signalling pathways and their roles in B-cell development, activation, and tolerance.

· Lymphoma and leukaemia studies: CD79B is a key diagnostic and therapeutic target in B-cell malignancies. Anti\u001eCD79B antibodies are widely used for immunophenotyping of B-cell lymphomas and leukaemias, as well as for monitoring minimal residual disease.

· Therapeutic antibody development: CD79B is being explored as a target for antibody-drug conjugates (ADCs) in B-cell cancers. Recombinant CD79B proteins serve as essential reagents for immunisation, antibody screening, and binding assays.

How to Choose and Buy?

Selecting the right VEGF, CD171, or CD79B antibody or protein depends on your experimental application (WB, IHC, flow cytometry, ELISA), species reactivity, and whether you require labelling (e.g., biotin, fluorescent dyes). High specificity, validated performance, and flexible formats are critical for reproducible results.

At BOT Bioscience, we are committed to providing premium-quality antibodies and recombinant proteins to support your cutting\u001eedge research in angiogenesis, neuro-oncology, and B-cell immunology. Our product portfolio features:

For researchers interested in exploring VEGF, CD171, or CD79B antibodies and proteins, BOT Bioscience offers custom synthesis and surface functionalisation services to meet your specific application requirements.